Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News Is biomarker-enriched trial design the key to solving schizophrenia cognition failures? Can biomarker-enriched trials solve schizophrenia cognition failures? Explore Alto Neuroscience’s strategy and what Phase 2 data could mean next. bySoujanya RaviFebruary 15, 2026